ClinicalTrials.gg
Not yet recruitingNCT07695740Updated Nov 6, 2026

Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma

A Phase 2 interventional study of YKST02 in Relapsed or Refractory Multiple Myeloma (RRMM), sponsored by Excyte Biopharma Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Primary conditionMultiple MyelomaRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Myeloma
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Multiple Myeloma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Excyte Biopharma Ltd · Phase 2, Interventional, and Treatment

Updated Nov 6, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 448 studies in Multiple Myeloma with a site in China — 238 open to participants now, 275 under way, 47 of them phase 3. Multiple Myeloma · China.

Planned enrollment
156th of 406
64 · median 40
Started
2027
with 2 others
Phase 2
60 of 448
33 open now
Primary completion
2030-12
later than 262 of 274 live
Registered
432nd of 448
by date

Among the 448 studies in Multiple Myeloma with a site in China, this one is the 156th largest by planned enrollment of the 406 interventional ones that give a count, is one of 3 that started in 2027, is one of 60 in phase 2, reaches primary completion later than 262 of the 274 other live ones, and was the 432nd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

238 of the 448 studies in Multiple Myeloma with a site in China are open now. Recruiting first, the newest first:

233 more — sign in →

All 238 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Multiple Myeloma with a site in China, or all of them as a file.
02

Study summary

The goal of this Phase 2 clinical trial is to learn whether YKST02 is effective and safe in adults with relapsed or refractory multiple myeloma. The study will also evaluate how YKST02 is processed by the body (pharmacokinetics), how it affects the body (pharmacodynamics), and whether it causes the body to produce anti-drug antibodies.

The main questions it aims to answer are:

Does YKST02 demonstrate clinical efficacy in adults with relapsed or refractory multiple myeloma? What side effects occur during treatment with YKST02? What are the pharmacokinetic, pharmacodynamic, and immunogenicity characteristics of YKST02?

Participants will:

Complete screening assessments to determine whether they are eligible for the study.

Receive YKST02 by intravenous infusion according to the study treatment schedule.

Undergo regular assessments to evaluate treatment response and monitor safety. Provide blood and urine samples for pharmacokinetic, pharmacodynamic, and immunogenicity testing.

Complete follow-up visits after treatment discontinuation to monitor disease progression and survival.

Multiple myeloma is a cancer of plasma cells that remains incurable despite advances in treatment. Although currently available therapies can improve outcomes, most patients eventually experience disease relapse or become refractory to treatment.

YKST02 is an investigational humanized bispecific antibody targeting BCMA on myeloma cells and CD3 on T cells. Simultaneous binding to BCMA and CD3 may activate T cells and promote tumor cell killing.

This is a multicenter, open-label study consisting of two parts (Phase IIa and Phase IIb). In Phase IIa, participants will initially receive YKST02 at the starting dose level. Safety and efficacy data from this part of the study will be reviewed to determine the dose to be evaluated in Phase IIb.

Read the detailed description

Relapsed or refractory multiple myeloma (RRMM) remains an incurable plasma cell malignancy despite substantial advances in treatment. Although currently available therapies, including proteasome inhibitors, immunomodulatory agents, anti-CD38 monoclonal antibodies, autologous stem cell transplantation, and B-cell maturation antigen (BCMA)-targeted therapies, have improved clinical outcomes, most patients eventually experience disease progression or relapse. Therefore, additional treatment options remain needed.

BCMA is highly expressed on malignant plasma cells and has emerged as an important therapeutic target for multiple myeloma.

YKST02 is an investigational humanized bispecific antibody targeting BCMA on myeloma cells and CD3 on T cells. Through simultaneous binding to BCMA and CD3, YKST02 is intended to redirect T cells to BCMA-expressing tumor cells, resulting in T-cell activation and tumor cell killing.

This is a multicenter, open-label, Phase 2 study designed to evaluate the efficacy, safety, pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity of YKST02 in adults with relapsed or refractory multiple myeloma.

Approximately 39 to 64 participants will be enrolled across multiple study centers in China, depending on the number of dose cohorts evaluated in Phase IIa.

The study consists of two parts. Phase IIa is designed to evaluate the safety and efficacy of YKST02 and to support selection of the dose for further evaluation in Phase IIb. Phase IIb will further evaluate the efficacy, safety, pharmacokinetics, immunogenicity, and pharmacodynamics of YKST02 at the selected dose.

Participants who meet all eligibility criteria will receive YKST02 according to the protocol-defined treatment schedule and undergo regular efficacy and safety assessments throughout the study. Blood and urine samples will be collected for pharmacokinetic, pharmacodynamic, and immunogenicity evaluations.

Participants will continue treatment until disease progression, unacceptable toxicity, withdrawal of consent, completion of the protocol-defined treatment period, or another protocol-defined discontinuation criterion. After treatment discontinuation, participants will enter follow-up for disease progression and survival.

03

Conditions studied

  • Relapsed or Refractory Multiple Myeloma (RRMM)

Browse trials for

Keywords

  • Relapsed or Refractory Multiple Myeloma
  • Bispecific Antibodies
  • YKST02
  • BCMA
  • CD3
04

In context

Multiple Myeloma Reclassified

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

This study's planned enrollment of 64 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.

Browse Multiple Myeloma studies →

Lead sponsor

Excyte Biopharma Ltd is the lead sponsor of 7 studies on the registry; 7 are open to participants now.

Compared within Multiple Myeloma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able and willing to provide written (or consent provided by a legally authorized representative, where applicable) and comply with all study procedures.
  • Diagnosis of multiple myeloma according to the 2016 International Myeloma Working Group (IMWG) diagnostic criteria.
  • multiple myeloma after at least two , including prior exposure to a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
  • as defined in the study protocol.
  • (ECOG) performance status of 0 or 1.
  • Estimated of at least 12 weeks.
  • Recovery from toxicities related to prior anticancer therapy to an acceptable level before study treatment (except alopecia).
  • Adequate hematologic, hepatic, renal, and coagulation function based on protocol-specified laboratory criteria.
  • Women of must have a negative pregnancy test before study treatment and agree to use effective during the study and for 3 months after the last dose of study treatment.
  • Male participants must agree to use effective contraception during the study and for 3 months after the last dose of study treatment and must not donate sperm during this period.

Exclusion criteria

Exclusion Criteria:

  • Plasma cell leukemia, Waldenström macroglobulinemia, POEMS syndrome, or primary light-chain (AL) amyloidosis.
  • Prior treatment with any BCMA-targeted therapy, including BCMA-directed chimeric antigen receptor (CAR) T-cell therapy.
  • Recent anticancer therapy, medicinal product, radiotherapy, stem cell transplantation, or organ transplantation that does not meet the protocol-defined washout requirements.
  • Active (GvHD) requiring systemic treatment or active GvHD.
  • History of another within the past 5 years, except for adequately treated malignancies with negligible risk of recurrence, as specified in the protocol.
  • Symptomatic central nervous system (CNS) , , or evidence of uncontrolled CNS or leptomeningeal involvement that, in the investigator's judgment, makes the participant unsuitable for study participation.
  • History of clinically significant central nervous system disorders that may increase study risk or interfere with study participation.
  • Clinically significant cardiovascular disease, including recent acute coronary syndrome or coronary revascularization, uncontrolled arrhythmias, (NYHA) Class III or IV heart failure, clinically significant cardiac dysfunction, prolonged , or uncontrolled hypertension.
  • Known to monoclonal antibodies, human immunoglobulins, or any component of the study drug.
  • Major surgery or severe trauma shortly before study treatment, or planned major surgery during the study.
  • Requirement for systemic or other therapy for conditions other than multiple myeloma that does not meet protocol requirements.
  • Active or infection, positive (HIV) test, or other clinically significant uncontrolled infection requiring systemic therapy.
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
  • Pregnant or breastfeeding women.
  • Known psychiatric illness or other conditions that may compromise the participant's ability to comply with study requirements.
  • Receipt of a live or within the protocol-defined period before the first dose of study treatment.
  • Any other clinically significant medical condition, laboratory abnormality, or circumstance that, in the investigator's judgment, would make participation in the study inappropriate.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    YKST02

    Drug: YKST02

Interventions

  • DrugYKST02

    Participants will receive YKST02 by intravenous infusion according to the protocol-defined treatment schedule. Treatment will continue until a protocol-defined treatment discontinuation criterion is met.

07

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    Overall response rate (ORR), defined as the proportion of participants achieving stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR), as assessed by the investigator according to the 2016 International Myeloma Working Group (IMWG) response criteria.

    Time frame: From first dose until disease progression or initiation of subsequent anti-cancer therapy, whichever occurs first (up to approximately 2 years).

Secondary outcomes

  1. Time to Response (TTR)

    Time from the first dose of YKST02 to the first documented objective response (partial response or better) according to the 2016 International Myeloma Working Group (IMWG) response criteria.

    Time frame: From first dose until first documented response (up to approximately 2 years)

  2. Progression-Free Survival (PFS)

    Time from the date of the first dose of YKST02 to the first documented disease progression or death from any cause, whichever occurs first, according to the 2016 IMWG response criteria.

    Time frame: From first dose until disease progression, death, or end of study (up to approximately 2 years)

  3. Duration of Response (DOR)

    Time from the first documented objective response to the first documented disease progression or death from any cause, whichever occurs first, according to the 2016 IMWG response criteria.

    Time frame: From first documented response until disease progression, death, or end of study (up to approximately 2 years)

  4. Overall Survival (OS)

    Time from the date of the first dose of YKST02 to death from any cause. Participants without documented death will be censored at the earlier of the last date known to be alive or the study cutoff date.

    Time frame: From the date of first dose until death from any cause or study completion

  5. Minimal Residual Disease (MRD) Negativity Rate

    Proportion of participants who achieve minimal residual disease (MRD) negativity. MRD assessment will be performed in participants who achieve complete response (CR) or better.

    Time frame: From first dose through 28 days after the last dose (up to approximately 2 years)

  6. Number of Participants with Adverse Events (AEs)

    An adverse event (AE) is any untoward medical occurrence in a participant administered the investigational product. An AE may be manifested as a sign, symptom, disease, or abnormal laboratory finding and does not necessarily have a causal relationship with the investigational product.

    Time frame: From the first dose through 28 days after the last dose (up to approximately 2 years).

  7. Number of Participants with Serious Adverse Events (SAEs)

    A serious adverse event (SAE) is an adverse event that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly or birth defect, or is considered an important medical event.

    Time frame: From the first dose through 28 days after the last dose (up to approximately 2 years).

  8. Number of Participants with Clinically Significant Laboratory Abnormalities

    Number of participants with treatment-emergent clinically significant laboratory abnormalities, as assessed by the investigator.

    Time frame: From first dose through 28 days after the last dose (up to approximately 2 years)

  9. Eastern Cooperative Oncology Group (ECOG) performance status

    Changes from baseline in Eastern Cooperative Oncology Group (ECOG) performance status, assessed using the ECOG Performance Status scale (scores range from 0 to 5, with lower scores indicating better functional status).

    Time frame: From first dose through 28 days after the last dose (up to approximately 2 years)

  10. Incidence of Anti-drug Antibodies (ADA)

    Proportion of participants who develop anti-drug antibodies (ADA) following administration of YKST02.

    Time frame: From first dose through 28 days after the last dose (up to approximately 2 years)

  11. Incidence of Neutralizing Antibodies (NAb)

    Proportion of ADA-positive participants who develop neutralizing antibodies (NAb).

    Time frame: From first dose through 28 days after the last dose (up to approximately 2 years)

  12. Area Under the Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t)

    Area under the serum concentration-time curve from time zero to the last quantifiable concentration (AUC0-t) of YKST02.

    Time frame: From first dose through end of PK sampling (up to approximately 2 years)

  13. Maximum Observed Serum Concentration (Cmax)

    Maximum observed serum concentration (Cmax) of YKST02 following study drug administration.

    Time frame: From first dose through end of PK sampling (up to approximately 2 years)

  14. Time to Maximum Serum Concentration (Tmax)

    Time to maximum observed serum concentration (Tmax) of YKST02 following study drug administration.

    Time frame: From first dose through end of PK sampling (up to approximately 2 years)

  15. Terminal Elimination Half-life (t½)

    Terminal elimination half-life (t½) of YKST02 estimated using noncompartmental pharmacokinetic analysis.

    Time frame: From first dose through end of PK sampling (up to approximately 2 years)

08

Study locations

1 site
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2027; primary completion for Dec 2030, 36 months later.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's planned 36 months is close to that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Sep 2026 → Dec 2027, primary completion Sep 2029 → Dec 2030 and completion Sep 2029 → Dec 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2026
First posted
Jul 10, 2026
StartEst.
Dec 2027was Sep 2026
Primary completionEst.
Dec 2030was Sep 2029
CompletionEst.
Dec 2030was Sep 2029
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Dec 2027
Nov 6, 2026
Primary completion
Sep 2029→Dec 2030
Nov 6, 2026
Study completion
Sep 2029→Dec 2030
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Start date Sep 2026→Dec 2027
    Primary completion Sep 2029→Dec 2030
    Study completion Sep 2029→Dec 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07695740
Lead sponsor
Excyte Biopharma Ltd
Responsible party
Sponsor
First posted
Jul 10, 2026
Start date
Dec 2027 (estimated)
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 6, 2026

Study contacts

Wenming Chen, MD
Contact
13910107759@163.com
+86-13910107759

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: YKST02

Start the discussion